NCT05415943已完成不适用
An Open-label, Multicentre, Single-arm Safety and Efficacy Clinical Investigation of Diagnostic Microprobe (inPROBE) for the Assessment of HER2 Receptor Expression in Population of Women at High Risk of Breast Cancer
SDS Optic S.A.4 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2022年8月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 4
- 主要终点
- Preliminary determination of HER2 receptor concentration ranges detected with inPROBE corresponding to HER2 receptor status (positive/negative) as determined by current diagnostic standard (IHC/FISH).
研究概览
简要总结
The purpose of this study is to preliminarily determine the correlation of HER2 receptor levels detected with the inPROBE diagnostic probe relative to receptor status as determined by standard methods (IHC/FISH), in women with both HER2-positive and HER2-negative breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Provision of written informed consent to participate in the clinical investigation;
- •Female patient aged ≥ 18 to ≤ 75 years;
- •The patient's overall health status as determined by Eastern Cooperative Oncology Group (ECOG) from 0 to 1;
- •Preserved full ability to communicate with the investigator and to understand and comply with the requirements of the Clinical investigation plan;
- •High likelihood of attending follow-up appointments in accordance with the study design and completing this study in accordance with this Clinical investigation plan.
- •The presence of a malignant neoplasm (breast cancer) confirmed by histopathologic examination of material from a gross needle biopsy of the tumor, with specific HER2 receptor status.
- •Patient referred for surgical treatment of breast cancer.
排除标准
- •History of treatment with trastuzumab, or other HER 2 receptor-binding antibody, as part of neoadjuvant (induction) therapy for currently diagnosed and treated breast cancer.
- •A skin disorder that prevents or contraindicates to perform a probe examination in the opinion of the investigator;
- •Breast inflammation/infection on the day of the probe examination;
- •Allergy to any component of the medical device that is the subject of this clinical investigation;
- •An implant in the breast where the inPROBE study and surgery will be performed;
- •Any physical or psychiatric condition, or laboratory test values outside the normal range, which in the opinion of the investigator constitute a contraindication to the patient's participation in this clinical investigation or pose a risk of exclusion from the study or premature termination of participation in the study;
- •Any clinically significant abnormality in physical examination, vital signs, or laboratory tests that, in the opinion of the investigator, is a contraindication to participation in this clinical trial;
- •Pregnancy or breastfeeding;
- •Participation in another clinical trial within 30 days prior to signing informed consent to participate in this clinical investigation;
结局指标
主要结局
Preliminary determination of HER2 receptor concentration ranges detected with inPROBE corresponding to HER2 receptor status (positive/negative) as determined by current diagnostic standard (IHC/FISH).
时间窗: Day 1
次要结局
- The occurrence of defects, failures, and fractures of the inPROBE probe during the diagnostic procedure leading to AE/ SAE.(Day 1 - Day 14)
- Comparison of the correlation of HER2 receptor concentrations detected by the inPROBE probe located in the tumor and in the immediate tumor area in HER2 positive patients.(Day 1)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
不适用
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCRRecurrent or Metastatic Breast CancerNCT03947736Chinese Academy of Medical Sciences200
进行中（未招募）
不适用
Tailoring treatment for HER2-positive early breast cancerHER2-positive early breast cancerMalignant neoplasm of breastCancerISRCTN81408940Institute of Cancer Research720
招募中
不适用
The Effects of HER2 Receptor Signaling on Human Brown Fat ActivityBreast CancerNCT06222957Rigshospitalet, Denmark30
进行中（未招募）
2 期
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLCHER2-mutant Non-Small Cell Lung CancerNCT05246514AstraZeneca72
招募中
1 期
Phase I clinical study on the safety of HER2-specific chimeric antigen receptor (CAR) gene-modified T cell therapyHER2 positive osteosarcoma/soft tissue sarcoma and gynecologic malignancyJPRN-jRCT2033220088Yozo Nakazawa12